Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01359982 | Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects(DINAMIC) | completed | Phase 1 | 26 | EpicentRx, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT04207190 | Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT02383368 | A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma | completed | Phase 1 | 39 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 23 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03586999 | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | completed | Phase 1 / Phase 2 | 18 | University of Colorado, DenverOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04714372 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | completed | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT01915498 | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | completed | Phase 1 / Phase 2 | 345 | CelgeneINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT03323034 | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03340766 | Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)(HARBOUR) | completed | Phase 1 | 31 | AmgenINDUSTRY | 6 | Oct 17, 2024 | clinicaltrials |
| NCT03941769 | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | completed | Phase 1 / Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT03989466 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03441048 | Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03936465 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | completed | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 2, 2024 | clinicaltrials |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma | completed | Phase 1 | 4 | PfizerINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02939183 | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma(INTREPID-1) | completed | Phase 1 | 61 | AmgenINDUSTRY | 4 | Sep 26, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02484391 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | completed | Phase 1 | 48 | Wake Forest University Health SciencesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02529852 | A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | completed | Phase 1 / Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04017546 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS | completed | Phase 1 | 14 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | completed | Phase 1 | 39 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT04827069 | A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) | completed | Phase 1 | 75 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT06586671 | A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) | completed | Phase 1 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03814005 | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems | completed | Phase 1 | 17 | TakedaINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 2 | Aug 27, 2024 | clinicaltrials |
| NCT02594384 | A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma(LAM-002A/NHL) | completed | Phase 1 | 62 | OrphAI TherapeuticsINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03829020 | Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Mayo ClinicOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | completed | Phase 1 | 18 | Calibr, a division of Scripps ResearchOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT00487305 | Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma | completed | Phase 1 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05326516 | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | completed | Phase 1 | 30 | Syndax PharmaceuticalsINDUSTRY | 2 | Aug 13, 2024 | clinicaltrials |
| NCT02192021 | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)(MNA-D) | completed | Phase 1 | 20 | Falo, Louis, MDOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03399331 | Honey or Olive Oil for Treating Oral Mucositis in Children and Adults With Leukemia Receiving Intensive Chemotherapy | completed | Phase 1 | 45 | American University of Beirut Medical CenterOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | completed | Phase 1 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02113982 | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 138 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06527781 | A Study of PD5K3 in Healthy Adult Volunteers | completed | Phase 1 | 28 | Chongqing Peg-Bio Biopharm Co., Ltd.INDUSTRY | 1 | Jul 30, 2024 | clinicaltrials |
| NCT02148913 | Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma | completed | Phase 1 | 18 | Corewell Health WestOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04394650 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 78 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04649112 | Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies | completed | Phase 1 | 13 | Precision BioSciences, Inc.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT01664910 | CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2024source: clinicaltrials